It is important to note that there are strict criteria to be considered a candidate for these procedures
For patients with high cardiovascular risk, additional options include PCSK9 inhibitors and newer agents such as inclisiran (NICE TA733) and bempedoic acid (NICE TA694)
Otherwise, attend A&E
Member of the Latinoamerican Board of Eli Lilly and Sanofi Aventis Member of the National Board of the following laboratories: Novo Nordisk, Novartis, GlaxoSmithKlein Sanofi, Aventis, Boheringer Ingelheim, Bristol Myers, Astra Zeneca Main investigator of Protocols from: Eli Lilly, Novo Nordisk, Novartis, GlaxoSmithKlein, Takeda, PPDF, Pfizer, Merck Sharp Dome, Amgen, Roche, Minimed, Quintiles Speakers of the former laboratories
Finally, we show that GSH synthesis in the liver suppresses the activity of the antioxidant transcription factor nuclear factor erythroid 2-related factor 2 (NFE2L2, also known as NRF2)